Clear All
767 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Estrogens, Esterified Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est 2.5 mg Hormonal Therapy Estrogen Yes 1977 In Use
NA Cysteamine Bitartrate Procysbi 25mg, 75mg, 300mg Chemotherapy Cystine-Depleting Agent Yes 2013 In Use
NA Dabrafenib Tafinlar 50 mg Chemotherapy Tyrosine Kinase Inhibitor BRAF Yes 2013 Jan 1, 2004 In Use
NA Afatinib Gliotrif 20 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2013 In Use
NA Dasatinib Sprycel 100 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Bexarotene Targretin 75mg Chemotherapy Immunomodulator Retinoic Acid Derivative Yes 2014 In Use
NA Nilutamide Anadron, Nilandron 150 mg Hormonal Therapy Androgen Receptor Inhibitor Yes 1996 In Use
NA Lenalidomide Revlimid 5 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2005 In Use
NA Avapritinib Ayvakit 50mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Cyclophosphamide Cyclophosphamide oral 50 mg Chemotherapy Alkylating Agent Nitrogen Mustard Yes 1959 In Use
NA Anagrelide Agrylin 1mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
NA Nilotinib Tasigna 150 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
NA Anastrozole Arimidex 0.5 mg Hormonal Therapy Aromatase Inhibitor Yes 1995 In Use
NA Apalutamide Erleada 60mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2018 In Use
NA Bicalutamide Casodex 50 mg Hormonal Therapy Androgen Receptor Inhibitor non-steriodal Yes 1995 In Use
NA Dacomitinib Vizimpro 15mg, 30mg, 45mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2018 In Use
NA Toremifene Citrate Fareston 60 mg Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Yes 1997 In Use
NA Tivozanib Fotivda 0.89mg, 1.34mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2021 In Use
NA Cabozantinib Cometriq 20 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Dasatinib Sprycel 50 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Trametinib Mekinist 2 mg Chemotherapy MEK Inhibitor BRAF Yes 2013 In Use
NA Tepotinib Hydrochloride Tepmetko 225mg Chemotherapy Tyrosine Kinase Inhibitor MET Yes 2021 In Use
NA Palbociclib Ibrance 75 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
NA Capmatinib Tabrecta 150mg, 200mg Chemotherapy Tyrosine Kinase Inhibitor MET Yes 2020 In Use
NA Palbociclib Ibrance 100 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.